View in EDS HTML Full Text PDF Full Text

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

Saved in:
Bibliographic Details
Title: Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Authors: Thaçi, Diamant1 (AUTHOR) diamant.thaci@uksh.de, Strober, Bruce2 (AUTHOR), Gordon, Kenneth B.3 (AUTHOR), Foley, Peter4 (AUTHOR), Gooderham, Melinda5 (AUTHOR), Morita, Akimichi6 (AUTHOR), Papp, Kim A.7 (AUTHOR), Puig, Lluís8 (AUTHOR), Menter, M. Alan9 (AUTHOR), Colombo, Matthew J.10 (AUTHOR), Elbez, Yedid10 (AUTHOR), Kisa, Renata M.10 (AUTHOR), Ye, June10 (AUTHOR), Napoli, Andrew A.10 (AUTHOR), Wei, Lan10 (AUTHOR), Banerjee, Subhashis10 (AUTHOR), Merola, Joseph F.11 (AUTHOR), Gottlieb, Alice B.12 (AUTHOR)
Source: Dermatology & Therapy. Feb2022, Vol. 12 Issue 2, p495-510. 16p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938210
DOI:10.1007/s13555-021-00649-y